adjuvanted
Showing 1 - 25 of 707
Hiv Trial in Amsterdam (BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum) Dosage)
Not yet recruiting
- Hiv
- BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum) Dosage
-
Amsterdam, NetherlandsThe Amsterdam University Medical Centers
Aug 2, 2023
Rabies, Prevention Trial (PIKA-adjuvanted inactivated rabies vaccine, Rabipur)
Not yet recruiting
- Rabies
- Prevention
- PIKA-adjuvanted inactivated rabies vaccine
- Rabipur
- (no location specified)
Dec 28, 2022
Hiv Trial (BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum))
Not yet recruiting
- Hiv
- BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum)
- (no location specified)
May 8, 2023
Hepatitis B Trial in Cambridge (GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide, GSK's HBsAg candidate vaccine
Recruiting
- Hepatitis B
- GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide
- +4 more
-
Cambridge, United KingdomGSK Investigational Site
Jan 12, 2023
Influenza Trial in Lima (FLUAD Quadrivalent, FluQuadri)
Active, not recruiting
- Influenza
- FLUAD Quadrivalent
- FluQuadri
-
Lima, Peru
- +1 more
Sep 19, 2023
Influenza, Human, Infections, Respiratory Tract Infections Trial in Philippines, United States (Low dose A/H2N3c + standard dose
Not yet recruiting
- Influenza, Human
- +4 more
- Low dose A/H2N3c + standard dose MF59
- +5 more
-
Rockville, Maryland
- +7 more
May 26, 2023
Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults
Recruiting
- Influenza
- +2 more
- Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)
- High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
-
Oakland, CaliforniaKaiser Permanente Northern California (entire region)
Sep 1, 2023
Healthy Trial (763SIP8/MPLA-5 vaccine)
Not yet recruiting
- Healthy
- 763SIP8/MPLA-5 vaccine
- (no location specified)
Mar 15, 2023
Pain, Quality of Life, Injection Site Reaction Trial in Durham (FLUAD® Quadrivalent, Fluzone® HD Quadrivalent, SHINGRIX®)
Recruiting
- Pain
- +3 more
- FLUAD® Quadrivalent
- +2 more
-
Durham, North CarolinaDuke University
Jan 19, 2023
HIV-1-infection Trial in Amsterdam (ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes)
Active, not recruiting
- HIV-1-infection
- ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes
-
Amsterdam, Noord-Holland, NetherlandsAmsterdam University Medical Centers, location AMC
Jan 31, 2023
Influenza Trial in Ghent (TETRALITE)
Active, not recruiting
- Influenza
- TETRALITE
-
Ghent, BelgiumCEVAC, University Hospital
Nov 16, 2022
Typhoid Fever Trial (TYP04A Low Dose without adjuvant investigational vaccine, TYP04B Full Dose without adjuvant investigational
Not yet recruiting
- Typhoid Fever
- TYP04A Low Dose without adjuvant investigational vaccine
- +5 more
- (no location specified)
Nov 4, 2022
Hepatitis B Trial in Baltimore, Falls Church (Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B])
Withdrawn
- Hepatitis B
- Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]
-
Baltimore, Maryland
- +1 more
Jul 19, 2022
Influenza, Human Trial in Georgia, Turkey (aQIV, QIV)
Not yet recruiting
- Influenza, Human
- aQIV
- QIV
-
Batumi, Georgia
- +16 more
Oct 11, 2023
COVID-19 Trial (GBP510 adjuvanted with AS03, Placebo (Normal Saline))
Not yet recruiting
- COVID-19
- GBP510 adjuvanted with AS03
- Placebo (Normal Saline)
- (no location specified)
Aug 11, 2022
Chikungunya Virus Trial in Lenexa (CHIKV VLP, adjuvanted)
Completed
- Chikungunya Virus
- CHIKV VLP, adjuvanted
-
Lenexa, KansasJohnson County ClinTrials
Jul 18, 2022
HIV Trial in Boston, Seattle, Nairobi (BG505 SOSIP.664 gp140, adjuvanted, Placebo)
Active, not recruiting
- HIV Infections
- BG505 SOSIP.664 gp140, adjuvanted
- Placebo
-
Boston, Massachusetts
- +2 more
May 6, 2022
Zoster, Systemic Lupus Erythematosus, Vaccine Reaction Trial in Seoul (Shingrix, Placebo)
Recruiting
- Zoster
- +2 more
- Shingrix
- Placebo
-
Seoul, Korea, Republic ofSeoul National University Hospital
Aug 17, 2023
Epstein-Barr Virus Infection, Infectious Mononucleosis, Herpesvirus Trial run by the National Institute of Allergy and
Not yet recruiting
- Epstein-Barr Virus Infection
- +2 more
- Matrix-M1 Adjuvant
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Poliomyelitis Trial in Dhaka (SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot A, SII Inactivated Salk Polio Vaccine
Recruiting
- Poliomyelitis
- SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot A
- +3 more
-
Dhaka, BangladeshInternational Centre for Diarrhoeal Disease Research, Bangladesh
Dec 24, 2022
Cervical Intraepithelial Neoplasia Trial (HPV9 High formulation, HPV9 Medium formulation, HPV9 Low formulation)
Not yet recruiting
- Cervical Intraepithelial Neoplasia
- HPV9 High formulation
- +3 more
- (no location specified)
Aug 10, 2022
COVID-19 Trial in Bloemfontein, Pretoria, Soweto (Candidate vaccine, SCB-2020S, Candidate vaccine, SCB-2019, Squalene based
Active, not recruiting
- COVID-19
- Candidate vaccine, SCB-2020S
- +3 more
-
Bloemfontein, South Africa
- +2 more
Oct 18, 2022
COVID-19, Vaccine Reaction Trial in Paris (BNT162b2, CoV2 preS dTM adjuvanted vaccine (D614), Sanofi/GSK, CoV2 preS dTM
Active, not recruiting
- COVID-19
- Vaccine Reaction
- BNT162b2
- +2 more
-
Paris, FranceGH Broca-Cochin-Hôtel-Dieu CIC 1417 Cochin-Pasteur
Jul 7, 2022
Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM) Trial in Rochester (Shingrix vaccine)
Completed
- Chronic Lymphocytic Leukemia (CLL)
- Waldenstrom Macroglobulinemia (WM)
- Shingrix vaccine
-
Rochester, New YorkUniversity of Rochester
Jan 9, 2023
COVID-19 Trial in Kyiv, Vinnitsa (CpG 1018/Alum-adjuvanted SCB-2019 vaccine, Havrix, Placebo; 0.9% saline)
Terminated
- COVID-19
- CpG 1018/Alum-adjuvanted SCB-2019 vaccine
- +2 more
-
Kyiv, Ukraine
- +3 more
May 19, 2022